Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African American Ethnicity

被引:20
|
作者
Babaoglu, Hakan [1 ,2 ]
Li, Jessica [1 ]
Goldman, Daniel [1 ]
Magder, Laurence S. [3 ]
Petri, Michelle [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA
[2] Gazi Univ, Sch Med, Ankara, Turkey
[3] Univ Maryland, Baltimore, MD 21201 USA
关键词
MULTIETHNIC US COHORT; INITIAL VALIDATION; REVISED CRITERIA; DAMAGE INDEX; ERYTHEMATOSUS; LUMINA; NEPHRITIS; SURVIVAL; HYDROXYCHLOROQUINE; CLASSIFICATION;
D O I
10.1002/acr.24063
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Lupus low disease activity state (LLDAS) is a potential treat-to-target goal in systemic lupus erythematosus (SLE). This study determined predictors of time to reach LLDAS in a longitudinal cohort. Methods Patients were grouped according to LLDAS status at cohort entry. Those who did not satisfy LLDAS at cohort entry were analyzed prospectively. The Kaplan-Meier approach was used to estimate the time to LLDAS. Cox regression was used to identify patient characteristics that were associated with time to LLDAS. Results The probability of LLDAS attainment within 1 year was 52% for Caucasians, 36% for African Americans, and 33% for SLE patients with renal involvement. The median time to LLDAS was 1.1 years. In multivariable models, African American ethnicity, baseline prednisone >10 mg daily, hypocomplementemia, baseline damage, and baseline renal activity remained significant predictors of longer time to attain LLDAS, while disease duration LLDAS is potentially attainable in the majority of SLE patients. The time to LLDAS was found to be longer in African American patients with SLE. Characteristics of African American patients with SLE, such as renal activity and hypocomplementemia, were also independent predictors of slower attainment of LLDAS. These findings point to the need to include African American patients with SLE in both clinical and pharmaceutical research.
引用
收藏
页码:225 / 232
页数:8
相关论文
共 50 条
  • [31] LLDAS (Low Lupus Disease Activity State) and Remission Prevent Damage Accrual in Systemic Lupus Erythematosus (SLE) Patients in a Primarily Mestizo Cohort
    Ugarte-Gil, Manuel
    Gamboa-Cardenas, Rocio V.
    Reategui-Sokolova, Cristina
    Pimentel-Quiroz, Victor
    Medina, Mariela
    Elera-Fitzcarrald, Claudia
    Zevallos, Francisco
    Pastor-Asurza, Cesar A.
    Lofland, Jennifer
    Zazzetti, Federico
    Karyekar, Chetan
    Alarcon, Graciela
    Perich-Campos, Risto
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [32] PREDICTORS AND CLINICAL SIGNIFICANCE OF LUPUS LOW DISEASE ACTIVITY STATE 12 MONTHS AFTER LUPUS NEPHRITIS
    Cheung, C. K.
    Chan, S. C. W.
    Lau, C. S.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1096 - 1097
  • [33] Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study
    Golder, Vera
    Kandane-Rathnayake, Rangi
    Huq, Moth
    Nim, Hieu T.
    Louthrenoo, Worawit
    Luo, Shue Fen
    Wu, Yeong-jian Jan
    Lateef, Aisha
    Sockalingam, Sargunan
    Navarra, Sandra, V
    Zamora, Leonid
    Hamijoyo, Laniyati
    Katsumata, Yasuhiro
    Harigai, Masayoshi
    Chan, Madelynn
    O'Neill, Sean
    Goldblatt, Fiona
    Lau, Chak Sing
    Li, Zhan Guo
    Hoi, Alberta
    Nikpour, Mandan
    Morand, Eric F.
    LANCET RHEUMATOLOGY, 2019, 1 (02): : E95 - E102
  • [34] Lupus Low Disease Activity State as an Attainable Target in Lupus Nephritis Associated with Reduced Risk of Relapse
    Cheung, Chak Kwan
    Lau, Chak Sing
    Chan, Shirley Chiu Wai
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4512 - 4514
  • [35] Validity of systemic lupus erythematosus disease activity score (SLE-DAS) for definition of lupus low disease activity state (LLDAS)
    Abdelhady, Enas, I
    Rabie, Mona
    Hassan, Rofaida A.
    CLINICAL RHEUMATOLOGY, 2021, 40 (11) : 4553 - 4558
  • [36] Validity of systemic lupus erythematosus disease activity score (SLE-DAS) for definition of lupus low disease activity state (LLDAS)
    Enas I. Abdelhady
    Mona Rabie
    Rofaida A. Hassan
    Clinical Rheumatology, 2021, 40 : 4553 - 4558
  • [37] PRELIMINARY VALIDATION OF A LOW DISEASE ACTIVITY STATE IN SYSTEMIC LUPUS ERYTHEMATOSUS
    Franklyn, K.
    Morand, E.
    Hoi, A.
    Nikpour, M.
    INTERNAL MEDICINE JOURNAL, 2014, 44 : 36 - 36
  • [38] CONSENSUS DEFINITION OF A LOW DISEASE ACTIVITY STATE IN SYSTEMIC LUPUS ERYTHEMATOSUS
    Lau, C. S.
    Nikpour, M.
    Navarra, S. V.
    Louthrenoo, W.
    Lateef, A.
    Hamijoyo, L.
    Wahono, C. S.
    Chen, S. L.
    Jin, O.
    Hoi, A.
    Morand, E. F.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 267 - 267
  • [39] Remission and Low Lupus Disease Activity Status (LLDAS) Protect Lupus Patients from Damage Occurrence: Data from a Multi-Ethnic, Multinational Latin American Lupus Cohort
    Ugarte-Gil, Manuel
    Wojdyla, Daniel
    Pons-Estel, Guillermo J.
    Catoggio, Luis J.
    Drenkard, Cristina
    Sarano, Judith
    Berbotto, Guillermo
    Borba, Eduardo
    Sato, Emilia
    Brenol, Joao Carlos
    Uribe, Oscar
    Ramirez, Luis
    Guibert-Toledano, Marlene
    Massardo, Loreto
    Cardiel, Mario
    Silveira, Luis H.
    Chacon-Diaz, Rosa
    Alarcon, Graciela S.
    Pons-Estel, Bernado
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [40] CONSENSUS DEFINITION OF A LOW DISEASE ACTIVITY STATE IN SYSTEMIC LUPUS ERYTHEMATOSUS
    Morand, E.
    Lau, C.
    Navarra, S.
    Louthrenoo, W.
    Lateef, A.
    Hamijoyo, L.
    Wahono, C.
    Chen, S.
    Jin, O.
    Hoi, A.
    Nikpour, M.
    INTERNAL MEDICINE JOURNAL, 2013, 43 : 17 - 18